Aβ (amyloid β-peptide) has a central role in AD (Alzheimer's disease) where neuronal toxicity is linked to its extracellular and intracellular accumulation as oligomeric species. Searching for molecules that attenuate Aβ aggregation could uncover novel therapies for AD, but most studies in mammalian cells have inferred aggregation indirectly by assessing levels of secreted Aβ peptide. In the present study we establish a mammalian cell system for the direct visualization of Aβ formation by expression of an Aβ 42 -EGFP (enhanced green fluorescent protein) fusion protein in the human embryonic kidney cell line T-REx293, and use this to identify both macromolecules and small molecules that reduce aggregation and associated cell toxicity. Thus a molecular shield protein AavLEA1 [Aphelenchus avenae LEA (late embryogenesis abundant) protein 1], which limits aggregation of proteins with expanded poly(Q) repeats, is also effective against Aβ 42 -EGFP when co-expressed in T-REx293 cells. A screen of polysaccharide and small organic molecules from medicinal plants and fungi reveals one candidate in each category, PS5 (polysaccharide 5) and ganoderic acid DM respectively, with activity against Aβ. Both PS5 and ganoderic acid DM probably promote Aβ aggregate clearance indirectly through the proteasome. The model is therefore of value to study the effects of intracellular Aβ on cell physiology and to identify reagents that counteract those effects.
INTRODUCTION
Aβ (amyloid β-peptide) plays a primary role in the development of AD (Alzheimer's disease), a neurodegenerative condition characterized by protein conformational changes that lead to intracellular aggregates and extracellular senile plaques. Aβ consists of peptides that are 40-42 residue fragments of APP (amyloid precursor protein), a large type I membrane protein found in neurons [1] . Although the traditional view is that Aβ deposited extracellularly [2] , together with intracellular tau NFTs (neurofibrillary tangles) [3] , lead to disease progression, more recent evidence indicates that intracellular accumulation of Aβ oligomers is an early event in the pathogenesis of AD that precedes both NFT and Aβ plaque deposits [1, 4, 5] . Bayer and Wirths [6] reviewed evidence indicating that both synaptic dysfunction and neuron loss are a consequence of intraneuronal accumulation of Aβ, with the predominant form being Aβ 42 rather than Aβ 40 .
The intraneuronal Aβ pool is generated intracellularly within the ER (endoplasmic reticulum) and Golgi system and is secreted as part of the constitutive secretory pathway in normal as well as diseased tissue. In AD-affected brains, it accumulates intracellularly in the multivesicular bodies, endosomes/lysosomes, autophagosomes, ER, Golgi, mitochondria and the cytosol. Intra-organelle accumulation of Aβ appears to damage these organelles and affect cell viability. Further, uptake of extracellular Aβ, either receptor-mediated or through endocytosis, contributes to the intracellular Aβ load. Intracellular Aβ is produced as a monomer, but aggregates to form multimeric structures ranging from oligomers to high-molecularmass fibrils. Although monomeric Aβ is not considered neurotoxic, the oligomers are thought to be highly damaging [1, 6] .
Given the importance of intracellular Aβ 42 aggregation in the development of AD and its potential usefulness as a model system for the study of protein aggregation in cells, we have developed a version of Aβ tagged with a fluorescent protein, giving the fusion protein Aβ 42 -EGFP [enhanced GFP (green fluorescent protein)], and have expressed this in the mammalian cell line T-REx293. In previous work, we showed that some IDPs (intrinsically disordered proteins) can reduce aggregation of poly(Q) expansion proteins derived from the huntingtin protein associated with HD (Huntington's disease), another common neurodegenerative disease, in vitro and in mammalian cells [7, 8] . IDPs are also active against aggregating poly(A) species linked with oculopharyngeal muscular dystrophy [7, 9] . LEA (late embryogenesis abundant) proteins form part of this class of anti-aggregant IDPs and have been identified in many plants and invertebrates, where they are associated with tolerance to desiccation, osmotic and cold stresses [10, 11] . The mechanism of action of LEA proteins and other IDPs with anti-aggregation activity is distinct from that of molecular chaperones and we have therefore introduced the concept of a molecular shield [12, 13] , an IDP that acts by reducing the frequency of cohesive interactions of aggregating protein species, to explain this phenomenon.
In the present study, we examine the ability of a wellcharacterized LEA protein to combat aggregation of intracellular Aβ 42 -EGFP, but also explore the potential of this model to screen for other molecules with anti-aggregation activity. For this purpose, we investigated several purified polysaccharides and small molecules associated with traditional herbal medicines, some of which are used to treat neurodegenerative diseases and other conditions linked to ageing. We identify molecules in each category with activity against intracellular Aβ 42 -EGFP aggregates that appear to act by stimulating clearance mechanisms within cells, in contrast with the direct mode of interaction favoured by the LEA proteins.
MATERIALS AND METHODS

Vectors, constructs and antibodies
The pCDF-Aβ 42 -EGFP plasmid [14] was a gift from Dr David Moffet (Department of Chemistry and Biochemistry, Loyola Marymount University, Los Angeles, CA, U.S.A.). The Aβ 42 -EGFP sequence was PCR-amplified from pCDF-Aβ 42 -EGFP using the primers 5 -TCAGGTACCGCCACCATGGATGCGG-AATTT-3 and 5 -GTCTCTAGATTACTTGTACAGCTCGTC-CAT-3 , and was cloned into the KpnI and XbaI sites of the mammalian cell expression vector pcDNA3.3-TOPO (Invitrogen), generating pcDNA3-Aβ 42 -EGFP, which was validated by sequencing. The pEGFP-C1 and pmCherry plasmids were obtained from Clontech. The construction of AavLEA1 (Aphelenchus avenae LEA protein 1)-mCherry was described previously [8] . Primary and secondary antibodies used for immunoblotting were the monoclonal anti-GFP (Sigma; used at a dilution of 1:5000) and Aβ-specific 6E10 (Covance; used at 1:1000 dilution) and the horseradish peroxidase-linked ECL (enhanced chemiluminescence) reagent anti-mouse IgG (GE Healthcare; 1:3333 dilution) antibodies respectively.
Mammalian cells and transfections
T-REx293 (Invitrogen) and T-REx293-LEA15 cells [7] were grown at 37
• C in a 5 % CO 2 , 100 % relative humidity atmosphere in DMEM (Dulbecco's modified Eagle's medium) with 10 % FBS (fetal bovine serum), 5 mM glutamine, 500 units/ml penicillin, 0.5 mg/ml streptomycin (all from Sigma) and 5 μg/ml blasticidin (Invitrogen), and additionally 50 μg/ml hygromycin B (Sigma) for T-REx293-LEA15. For transient transfections, 0.75 μg of pcDNA3-Aβ 42 -EGFP plasmid was introduced into the cells using GeneJammer (Agilent Technologies) and expression was allowed to proceed for 24, 48 or 72 h. For Aav-lea-1 induction, 10 μg/ml of tetracycline, or an equivalent volume of 100 % ethanol as control, was added. In the stable cell line T-REx293-LEA15, the expression of AavLEA1 was detected by immunocytochemistry as described previously [7] . For drug treatment, the indicated amounts were added post-transfection and cells were treated for 24 h. As a positive control, 20 μM EGCG (epigallocatechin gallate; Sigma) was used. For negative controls, the cells were treated with an equivalent volume of either water or DMSO. To inhibit the ubiquitin-proteasome and autophagosome-lysosome pathways, 10 μM lactacystin and 10 mM 3MA (3-methyladenine) were added respectively.
Quantification of Aβ 42 -EGFP aggregates and cell death
Approximately 200 Aβ 42 -EGFP-positive cells were counted per sample for the presence of aggregates by confocal fluorescence microscopy. Whether an Aβ 42 -EGFP-positive cell has one or many aggregates, the aggregate score is one, and is otherwise scored as zero. Approximately 200 cells co-expressing both mCherry/AavLEA1-mCherry/AavLEA1 and Aβ 42 -EGFP were counted per sample. Nuclei were stained with DAPI (4 ,6-diamidino-2-phenylindole) and those that showed abnormal morphology indicative of necrosis or apoptosis (for example, fragmentation or pyknosis) were considered to be symptomatic of dead cells [15] . Since each experiment was carried out in triplicate and performed at least twice, Aβ 42 -EGFP aggregation and cell death are expressed in terms of odds ratio to encompass all experiments and their replicates. Images were acquired with a Zeiss LSM510 META confocal microscope [×63, 1.4 NA (numerical aperture) PlanApochromat objective] and Zeiss LSM 510 v3.2 software.
ProteoStat staining assay
A ProteoStat Amyloid Plaque Detection Kit (Enzo Life Sciences) was used to characterize Aβ 42 -EGFP aggregates. At 24 h posttransfection, cells were washed with PBS and fixed with 4 % paraformaldehyde for 30 min. After washing twice with PBS, the cells were permeabilized with 0.5 % Triton X-100 and 3 mM EDTA for 15 min at 4
• C. The cells were again washed twice with PBS and the ProteoStat dye was added at 1:4000 dilution for 30 min at room temperature (23
• C). The cells were mounted after washing twice in PBS and images were acquired with a confocal microscope.
Immunoblotting
At 24 h post-transfection, cells were harvested and lysed in lysis buffer [10 mM Tris/HCl, pH 6.8, 68.5 μM NaCl, 0.5 mM EGTA, 0.5 % Triton X-100, 5 % glycerol and Complete TM protease inhibitor cocktail (Roche Diagnostics)] for 30 min on ice. The lysates were quantified using a Nanodrop spectrophotometer and mixed with loading buffer (62.5 mM Tris/HCl, pH 6.8, 10 % glycerol, 0.2 % SDS, 5 % 2-mercaptoethanol and 0.05 % Bromophenol Blue). Samples were boiled (in some cases this step was skipped, as indicated in Figure 1 ) for 5 min followed by equal loading on SDS/PAGE gels. Immunoblotting was then conducted as described previously [9] .
Purification of polysaccharides
Polysaccharides were extracted and purified as described previously [16] . Briefly, after extraction with 80 % (v/v) ethanol at 50
• C, plant materials were collected and extracted at 95
• C with distilled water. The supernatant was then collected by centrifugation at 5000 g for 10 min and concentrated under reduced pressure at 40
• C, and the solution was precipitated with four volumes of ethanol. The precipitate was redissolved in distilled water and subjected to removal of proteins by the Sevag method [16a] . After dialysis (molecular mass cut-off, 3500 Da), the polysaccharide was recovered by freeze-drying.
Purification of small molecules
Small molecules were all isolated in the chemistry laboratory of the Shanghai Research Center for Modernization of Traditional Chinese Medicine. Isoliquiritigenin (compound 1 in Table 2 ) and protocatechuic acid (compound 2) were isolated from the caulis of Millettia reticulata. The pulverized caulis was refluxed with 95 % and 70 % ethanol successively. After removing the solvents under reduced pressure at 40
• C, the total extract was obtained. The extract was processed by solvent extraction and repeated column chromatography (silica gel) to yield compounds 1 and 2. Both compounds were further purified by column chromatography (Sephadex LH-20) with methanol elution. Atractylenolide III (compound 3) was isolated from the pulverized rhizoma of Atractylodes macrocephala by reflux (three times) with ethyl acetate. The extract was obtained after removing solvent under reduced pressure at 40
• C. Compound 3 was isolated by repeated column chromatography (silica gel) and finally purified by column chromatography (Sephadex LH-20) eluted with petroleum ether, chloroform and methanol (2:1:1). For compound 4, the pulverized caulis of Sargentodoxa cuneata was refluxed with 95 % ethanol three times. After removing solvent (as described above), the total extract was obtained using ethyl acetate, then chromatographed on a HP-20-filled column and finally purified on a Sephadex LH-20-filled column eluted with methanol to yield chlorogenic acid (4). For compounds 5 and 6, the seeds of Euphorbia lathyris were cold-soaked with 95 % ethanol. The total extract (after being concentrated as described above) was dispersed in water and then extracted with ethyl acetate. The ethyl acetate fraction was repeatedly chromatographed on silica gel columns to yield Euphorbia factor L3 (5) and Euphorbia factor L2 (6) . The procedures for the isolation and purification of GDA (ganoderic acid) D (compound 7) and GDA-DM (compound 8) were described previously [17] . All raw materials used above were validated by D.-a.G. The purities of the small molecules were all >98 % (by HPLC). The structures of all compounds were elucidated through their NMR and MS spectroscopic data and comparison with the reported literature.
ThT (thioflavin T) assay
Freeze-dried Aβ 1-42 peptide (0.5 mg; GenScript) was dissolved in 1,1,1-3,3,3-hexafluoro-2-propanol (Sigma) with shaking at 4
• C overnight. After distillation under nitrogen, the Aβ 1-42 peptide was dissolved in DMSO to a concentration of 200 μM and sonicated for 15 min. Aβ 1-42 stock solution (20 μl) was added to 180 μl of PBS (pH 7.4) containing 20 μM ThT (Sigma) and different concentrations of PS (polysaccharide) 5 or GDA-DM in 96-well plates, as required. EGCG (100 μg/ml; Sigma) was used as a positive control. Fluorescence was read at different time points (λ ex , 444 nm; λ em , 485 nm) using a microplate reader (Fluoroskan Ascent FL, Thermo Scientific).
Aβ 42 bacterial assay
The Escherichia coli ssTorA-Aβ-Bla (β-lactamase) strain was a gift from Professor Matthew DeLisa (School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, U.S.A.). The bacterial assay was performed as described previously [18] with slight modification. Cells grown overnight in LB (Luria-Bertani) medium containing 12.5 μg/ml chloramphenicol at 37
• C were diluted 1:100 and grown for 3 h in the same medium. Then, these exponential phase cultures were diluted 1:50 in LB containing 12.5 μg/ml chloramphenicol and 1 mM IPTG (isopropyl β-D-thiogalactopyranoside) with or without 50 μg/ml ampicillin selection. To detect any effect on Aβ 42 aggregation, different concentrations of PS5, GDA-DM and 100 μg/ml EGCG were added separately to the medium. The plates were incubated at 37
• C without shaking for 16 h and D 600 values were taken as an indicator of cell growth.
Statistics
Aggregate formation and cell death have been expressed in terms of odds ratios (logistic regression analysis): pooled estimates for the changes in aggregate formation/cell death resulting from perturbations assessed in multiple experiments were calculated as odds ratios with 95 % confidence intervals, for example, odds ratio of aggregation = [(percentage of cells expressing construct with aggregates in perturbation conditions/percentage of cells expressing construct without aggregates in perturbation conditions)/(percentage of cells expressing construct with aggregates in control conditions/percentage of cells expressing construct without aggregates in control conditions)]. Odds ratios were considered to be the most appropriate summary statistic for reporting multiple independent replicate experiments of this type because the percentage of cells with aggregates/dead cells under specified conditions can vary between experiments on different days, whereas the relative change in the proportion of aggregate-containing or dead cells induced by an experimental perturbation is expected to be more consistent. This method has been used previously [7] [8] [9] to allow analysis of data from multiple independent experiments. Odds ratios and P values were determined using SPSS 9 software. One-way ANOVA and Tukey post-hoc test using InStat3 (GraphPad Software) were performed for in vitro aggregation assays (ThT and bacterial assays) as described previously [7] . These experiments were performed at least twice.
RESULTS
Expression of Aβ 42 -EGFP in T-REx293 cells leads to aggregate formation and cell death
The human cell line T-REx293 was transiently transfected with either Aβ 42 -EGFP or EGFP-C1 (control; expresses EGFP only) plasmids and observed by confocal microscopy after 24 h. Whereas intracellular EGFP gave a relatively uniform green fluorescence, Aβ 42 -EGFP was distributed throughout the cell but formed clearly visible bright green aggregates of various sizes in a proportion of the transfected cells ( Figure 1A ). The Aβ 42 -EGFP aggregates were characterized using ProteoStat, an amyloidspecific red fluorescent dye [19] . Whereas negligible ProteoStat staining was observed in cells transfected with EGFP-C1 alone, positive red fluorescence was observed in the presence of the dye in Aβ 42 -EGFP-expressing cells, which co-localized with the green aggregates, consistent with them being of an amyloid nature ( Figure 1A ). This aggregating property of intracellular Aβ 42 -EGFP was further confirmed by immunoblotting cell extracts with Aβ-specific (6E10) and GFP-specific antibodies ( Figure 1B) . As well as monomeric Aβ 42 -EGFP, several highermolecular-mass bands representing oligomeric species were also observed using both antibodies, together with insoluble Aβ 42 -EGFP that remained in the stacking gel; in contrast, EGFP from the control cell transfection ran as a single band ( Figure 1B , lower panel). It should be noted that in the absence of boiling of samples before gel loading, although higher-molecular-mass oligomeric species were observed, not all of the lower-order species could be discerned. Therefore, in order to visualize the latter, the samples were boiled under denaturing conditions; however, this also resulted in some fragmentation of the aggregates. Compared with EGFP-C1 transfected controls, intracellular Aβ 42 -EGFP expression also resulted in substantially increased cell death as assessed by abnormal nuclear morphology (Figures 2A and 2B) .
A molecular shield reduces intracellular Aβ 42 -EGFP aggregation and corresponding cell death
Previously we showed that certain IDPs behaving as molecular shields, including some LEA proteins, are able to reduce aggregation of proteins containing expanded poly(Q) or poly(A) tracts [7] [8] [9] . We therefore tested whether one of these proteins, the nematode group 3 LEA protein AavLEA1, is also active against intracellular Aβ 42 -EGFP aggregation. When expressed as the fluorescent fusion protein AavLEA1-mCherry, it is a predominantly cytoplasmic protein, whereas mCherry alone is present throughout both cytoplasm and nucleus in T-REx293 cells. These expression patterns were unaltered when co-expressed with Aβ 42 -EGFP for 24 h (Figures 3A and 3B) . Furthermore, coexpression of AavLEA1-mCherry led to a significant decrease in the percentage of cells with microscopically visible Aβ 42 -EGFP aggregates compared with the mCherry control at 24 h and 48 h time points, with logistic regression analysis indicating P < 0.0001, a highly significant difference, in each case ( Figures 3C and 3D) . However, after 72 h this difference was no longer observed, suggesting that AavLEA1-mCherry was able to delay Aβ 42 -EGFP aggregation but did not abrogate it altogether ( Figure 3E ). This time-dependent anti-aggregation activity of the LEA protein against intracellular Aβ 42 -EGFP is reminiscent of that against poly(Q) aggregation and is consistent with a kinetic stabilization role [8] . Concurrent with its effect on Aβ 42 -EGFP aggregation, co-expressed AavLEA1-mCherry could also improve cell survival compared with mCherry controls (Figures 3F-3H ). Intriguingly, this was apparent at 72 h as well as earlier time points, perhaps indicating incomplete concordance of large aggregate formation with cell toxicity.
The ability of AavLEA1 to reduce intracellular Aβ 42 -EGFP aggregate formation was further confirmed by transiently expressing Aβ 42 -EGFP in the cell line T-REx293-LEA15, which contains a stably integrated copy of the gene encoding AavLEA1, Aav-lea-1. Gene expression is blocked by the TetR (tetracycline repressor) protein in these cells, but repression can be removed by addition of tetracycline to the medium [7] . Aβ 42 -EGFP was expressed for 48 h and AavLEA1 expression was induced either for the same length of time or 24 h before Aβ 42 -EGFP expression commenced, continuing for a further 48 h. Regardless of expression pattern, the IDP was able to reduce significantly the aggregation of Aβ 42 -EGFP amyloid (see Supplementary Figure  S1 at http://www.BiochemJ.org/bj/442/bj4420507add.htm).
Polysaccharides and small molecules from medicinal plants and fungi reduce intracellular Aβ 42 -EGFP aggregation and toxicity
Next we explored whether the Aβ 42 -EGFP intracellular aggregation system could be used as a platform to identify compounds with previously undescribed anti-aggregation activity.
We tested two classes of molecule, polysaccharides and small organic compounds, purified from plants or fungi used in TCMs (traditional Chinese medicines).
Water-soluble polysaccharides (final concentration 2 mg/ml) from eleven plant species (Table 1) were used individually to treat T-REx293 cells transfected with the Aβ 42 -EGFP construct; the number of cells containing visible aggregates was counted after 24 h. In the initial screens, several polysaccharides gave an apparent reduction in Aβ 42 -EGFP aggregation compared with the water-treated control. Of these, PS5 from Rubia cordifolia (common madder) emerged as the best candidate for further investigation, since it had no apparently detrimental effects on EGFP expression or the health of the cell. When cells were treated with PS5 at a concentration of 2 mg/ml, their morphology was not adversely affected ( Figure 4A ) and the number of Aβ 42 -EGFP aggregates was significantly reduced; a lower dose of this extract was not active, indicating a concentration-dependent effect ( Figure 4B ). Eight DMSO-soluble organic compounds (Table 2) , purified from plants and fungi used as TCMs, were also assessed and one of these, GDA-DM, was found to significantly and consistently reduce Aβ 42 -EGFP aggregation in T-REx293 cells compared with DMSOtreated controls. The anti-aggregation effect of GDA-DM showed dosage dependency, being apparent at concentrations 400 nM ( Figure 4C ), with the highest activity at 40 μM, which was used for subsequent experiments. Both PS5 and GDA-DM individually also reduced the toxicity of Aβ 42 -EGFP in T-REx293 cells, giving a significant reduction in cell death at the tested concentrations ( Figure 4D ). We also ascertained that the green tea constituent, EGCG, a known modulator of Aβ aggregation, was active in our screening method whereby it significantly reduced Aβ 42 -EGFP aggregation and cell death in mammalian cells compared with the control (see Supplementary Figure S2 at http://www.BiochemJ.org/bj/442/bj4420507add.htm).
To ask whether PS5 and GDA-DM could act in an additive manner, T-REx293 cells expressing Aβ 42 -EGFP were treated with both compounds simultaneously. Although individually these compounds showed a reduction in aggregation compared with the control, there was no further decrease when used together (see Supplementary Figure S3 at http://www.BiochemJ.org/bj/442/bj4420507add.htm), consistent with PS5 and GDA-DM operating by a similar mechanism that is saturated under the conditions used.
PS5 and GDA-DM attenuate intracellular Aβ 42 -EGFP aggregation indirectly
Previously we showed that AavLEA1 can reduce intracellular aggregation of a poly(Q) protein even when proteasomal and autophagic protein degradation systems were blocked, indicating that it prevents aggregate formation by direct interaction rather than by stimulating clearance pathways [7] . Similarly, when TREx293 cells were treated with the inhibitors lactacystin and 3MA (specific for the proteasome or autophagy respectively), AavLEA1-mCherry was still able to significantly reduce Aβ 42 -EGFP aggregation compared with the mCherry control ( Figure 5A ), even though the inhibitors caused a general increase in overall levels of aggregation (see Supplementary Figure  S4 at http://www.BiochemJ.org/bj/442/bj4420507add.htm). This suggests that the IDP acts by reducing Aβ 42 -EGFP aggregate formation, as it does with poly(Q) aggregates, rather than by stimulating aggregate clearance.
Since PS5 and GDA-DM were added to cell culture medium, rather than being produced intracellularly like Error bars indicate 95% confidence intervals for the odds ratios of two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. ns, not significant; OR, odds ratio.
AavLEA1-mCherry, either they act indirectly on Aβ 42 -EGFP aggregation or they (or their derivatives) must be able to enter cells efficiently. When both the proteasome and autophagy clearance systems were blocked in T-REx293 cells producing Aβ 42 -EGFP, neither PS5 nor GDA-DM was able to reduce levels of aggregation, indicating that these compounds might act by stimulation of one or both clearance routes ( Figure 5B ). When autophagic function was inhibited individually, we found that both PS5 and GDA-DM treatments were still effective at reducing Aβ 42 -EGFP aggregation compared with the nontreated control, suggesting that they do not modulate autophagy ( Figure 5C ). In contrast, when proteasome activity was inhibited by lactacystin, the ability of both PS5 and GDA-DM to reduce Aβ 42 -EGFP aggregation was impaired ( Figure 5D ). These results are consistent with the ability of both PS5 and GDA-DM to enhance clearance of intracellular Aβ 42 -EGFP aggregates via proteosomal degradation. 
PS5 and GDA-DM do not reduce Aβ 42 aggregation in vitro or in bacterial cells
If indeed PS5 and GDA-DM act on Aβ 42 aggregation indirectly, then they should not be able to reduce its aggregation in assays that require a direct interaction between the protective agent and its client. To test this we performed a ThT assay using synthetic Aβ 42 peptide and various concentrations of the two compounds individually. As a positive control, we used EGCG, which is known to reduce Aβ 42 aggregation by direct interaction with amyloid [20, 21] . We found that although, over the time course tested, EGCG was able to substantially reduce Aβ 42 aggregation, neither PS5 nor GDA-DM achieved the same result ( Figure 6 , and Supplementary Tables S1 and S2 at http://www.BiochemJ.org/bj/442/bj4420507add.htm). In the case of higher concentrations of PS5, a low level intrinsic fluorescence of the polysaccharide (results not shown) has the effect of raising overall fluorescence ( Figure 6A and Supplementary Table S1 ), but the trend line, indicating Aβ 42 aggregation, was not altered. Another assay for compounds which inhibit Aβ 42 aggregation and that penetrate to the cell interior was described previously in E. coli [18] . This is based on the folding quality control mechanism of the bacterial Tat (twin-arginine translocation) system where the efficiency with which Bla is translocated through Tat from the cytoplasm into the periplasm, thereby conferring ampicillin resistance, depends upon the folding characteristics of the polypeptide fused to it. Thus a chimaeric protein comprising the Tat signal (ss-TorA), Aβ 42 and Bla is unable to translocate to the periplasm due to Aβ 42 aggregation; bacteria are consequently ampicillin sensitive. However, certain small molecules are able to decrease Aβ 42 aggregation, allowing Bla translocation and growth on the antibiotic. Accordingly, E. coli expressing the ss-TorA-Aβ 42 -Bla chimaeric protein was able to grow in ampicillin in the presence of 100 μg/ml EGCG, but not with either PS5 or GDA-DM (see Supplementary Figure S5 and Supplementary Tables S3 and S4 at http://www.BiochemJ.org/bj/442/bj4420507add.htm). This result shows that both compounds are only effective at reducing Aβ 42 aggregation in the context of a mammalian cell environment and do not function in prokaryotes.
DISCUSSION
The Aβ 42 -EGFP fusion protein used in the present study does not fluoresce well when expressed in bacteria due to the effect of aggregation on the maturation of the EGFP fluorophore [14] . Inhibitors of aggregation can partially restore fluorescence, however, and this principle has been used in high-throughput screening protocols to identify anti-amyloidogenic molecules [14, 22] . In contrast, when transiently expressed in the mammalian cell line T-REx293, Aβ 42 -EGFP was sufficiently fluorescent to allow direct observation and quantification of aggregates by fluorescence microscopy, perhaps indicating a slower rate of aggregation than occurs in the prokaryotic cytoplasm. The fusion protein also causes cell death in mammalian cells and therefore it was possible to exploit this system to assess the effect of potentially protective agents on Aβ 42 aggregation and toxicity. Such a screening tool is currently lacking in mammalian cells, but would be useful for the discovery of candidates for combating AD and other intracellular Aβ-related diseases.
The well-characterized molecular shield protein AavLEA1 is known to reduce aggregation of poly(Q) proteins in mammalian cells [7] and was also found to combat intracellular Aβ 42 aggregation and the associated toxicity in the cell model in the present study. The activity shown by AavLEA1 is consistent with a preventative role and not a stimulation of protein degradation pathways via the proteasome or autophagosome. It is interesting to compare this activity with that of molecular chaperones, which are the first line of defence against protein aggregation, including that involving Aβ peptide. For example, various chaperones interact with intracellular Aβ and can inhibit cellular toxicity and the formation of oligomers or fibrils [23] [24] [25] [26] [27] . However, although the activities of molecular shield and molecular chaperone are superficially similar, the mechanism of action is distinct: whereas classical chaperones have welldefined three-dimensional structures and usually interact with their partners through hydrophobic patches, shield proteins are unstructured and highly hydrophilic, and probably do not form stable complexes with their clients [9, 13, 28] . Indeed, as with its activity against poly(Q) protein aggregates [7, 8] , it seems likely that AavLEA1 functions through a reduction in the rate of cohesive interaction of Aβ 42 -EGFP molecules, since its effect diminishes over time. A molecular shield therefore offers kinetic stabilization of aggregation-prone protein species, rather than their sequestration or disaggregation, as might a molecular chaperone.
We examined the suitability of the Aβ 42 -EGFP mammalian cell model for the identification of novel bioactive molecules when added to the extracellular medium. For this purpose we screened purified polysaccharides and small molecules extracted from plants and fungi used in TCMs. There have been several studies on the efficacy of TCMs in controlling AD, some of which are under clinical trial (reviewed in [29] [30] [31] ). Therefore TCMs provide an excellent source of potentially active molecules. From eleven polysaccharides and eight small molecules, we found one clear example in each category that was able to reduce Aβ 42 -EGFP aggregation and toxicity in mammalian cells. Further analysis indicated that, unlike chaperones or shield proteins, these compounds probably do not directly influence Aβ oligomer and/or fibril formation, but instead are likely to promote clearance of aggregates through the ubiquitin-proteasome degradation pathway. These results suggest that the Aβ 42 -EGFP mammalian cell model is of value not only for identifying novel activities able to modulate protein homoeostasis, but also for investigating their mechanism of action, whether this is intracellular or extracellular, direct or indirect. Several polysaccharides have been reported to have an effect on Aβ oligomer and/or fibril formation, either by direct interaction or via stimulation of cell defence mechanisms. For example: heparin, a highly sulphated glycosaminoglycan, can impede Aβ fibril formation directly [32] ; a polysaccharide extract from Lycium barbarum (wolfberry or goji berry) has neuroprotective effects against the toxicity of Aβ peptide [33] ; and chitosan, a polymer of D-glucosamine and N-acetyl-D-glucosamine subunits, reduces Aβ peptide formation resulting from oxidative stress in neuronal cells by induction of antioxidant and molecular chaperone systems [34] . The polysaccharide PS5 from R. cordifoli, shown here to reduce intracellular Aβ 42 -EGFP aggregation and cytotoxicity, has not previously been shown to have neuroprotective effects and therefore illustrates the potential of the Aβ 42 -EGFP mammalian cell model to uncover novel activities. Interestingly, however, a crude ethanol extract of R. cordifoli, probably containing smallmolecule actives, has also been shown to have neuroprotective properties in a mouse model [35] .
Ganoderma lucidum is an edible mushroom that is used in traditional medicine in Asia to treat many conditions, including cancer and diabetes [36] [37] [38] . Although it is indicated as a general anti-ageing treatment, it is not usually specified for neurodegenerative diseases. Its medicinal properties are attributed largely to polysaccharides and triterpenoids: GDA-DM [39] is one of many lanostanoid triterpenes isolated from the fruiting body of the mushroom. Although an aqueous extract of G. lucidum, comprising mostly polysaccharide, has some neuroprotective effect against Aβ peptide [40] , there are no reports currently of ganoderic acids exhibiting such activity. GDA-DM itself has been shown to inhibit production and binding of the androgen dihydrotestosterone to its receptor, thus potentially affecting prostate cancer cell growth [41] .
Both PS5 and GDA-DM probably reduce intracellular levels of Aβ 42 -EGFP aggregates by enhancing degradation by the proteasome, but they do not affect Aβ 42 aggregate formation directly, according to a ThT assay. Resveratrol, a cell-permeant polyphenolic compound from grapes, promotes proteasomal clearance of Aβ peptide [42] , but it was not shown whether aggregates are also removed. Furthermore, this compound has multiple effects on β-amyloid formation since it also triggers autophagic clearance of Aβ aggregates [43] and interacts directly with amyloid to reduce fibril, although not Aβ oligomer, formation [44, 45] . PS5 and GDA-DM therefore behave differently to resveratrol, but they share some functional characteristics. Since PS5 is a polysaccharide, it is likely to act on the cell exterior unless it is internalized and/or processed to its constituent sugar residues. GDA-DM, on the other hand, is cell permeant and thus is able to access intracellular targets. Nevertheless, both PS5 and GDA-DM could be affecting the same pathway since they do not show an increased effect when used additively. Their precise site of action is currently under investigation, but possibilities include direct stimulation of protease activity within the proteasome core or enhancement of Aβ peptide as a substrate, either through attenuation of its inhibitory effect on proteasome activity [46] or by promotion of Aβ 42 peptide ubiquitination [47] . 
Figure S3 The anti-aggregation effect of PS5 and GDA-DM is not additive
Cells were transfected with pcDNA3-Aβ 42 -EGFP and treated with either PS5 or GDA-DM, or both, at the indicated concentrations. Error bars indicate 95% confidence intervals for the odds ratios of two independent experiments. ***P < 0.001. OR, odds ratio.
Figure S4 Blocking cellular degradation pathways increases Aβ 42 -EGFP aggregation
pcDNA3-Aβ 42 -EGFP-transfected T-REx293 cells were treated with either 10 μM lactacystin (to block the proteasomal pathway) or 10 mM 3MA (to block the autophagic pathway), or both (to simultaneously block both pathways). Error bars indicate 95% confidence intervals for the odds ratios of two independent experiments. ***P < 0.001. OR, odds ratio. Figure 5A in the main paper) *P < 0.05; **P < 0.01; ***P < 0.001. ns, not significant. Figure 5B in the main paper) *P < 0.05; **P < 0.01; ***P < 0.001. ns, not significant. Figure 6A in the main paper)
The test was performed to assess whether there was any significant growth of E. coli between 0 h and 16 h. ***P < 0.001. Amp, ampicillin; ns, not significant. Figure 6A in the main paper)
The test was performed to assess whether there was any significant growth of E. coli between 0 h and 16 h. ***P < 0.001. Amp, ampicillin; ns, not significant. 
